Terbinafine hepatic impairment — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Do not supply until the prescriber reviews active liver-disease risk
Oral terbinafine can cause serious hepatotoxicity and is contraindicated or unsuitable in chronic or active liver disease. Existing biochemical abnormality and alcohol exposure require prescriber review before supply; another diagnosis or treatment strategy may be needed.
Reference: BNF: terbinafine: https://bnf.nice.org.uk/drugs/terbinafine/